About: Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
CDTX NASDAQ Cidara Therapeutics Inc
Cidara Therapeutics Inc share price
Atividade de preço de CDTX
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
CDTX price performance
quote.marketSignals